Skip to main content

pralatrexate

Generic: PRALATREXATE·Brand: FOLOTYN, PRALATREXATE

pralatrexate: 3 clinical trials tracked.

pralatrexate evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pralatrexate, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trials (3)

Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma

NCT07691450·Phase 1
Not yet recruiting

Primary endpoint: Occurrence of dose-limiting toxicities (DLT) (Arm A)

Interventionalopen40 targetStarted 2027-01Completion 2029-111 site · United StatesCity of Hope Medical Center

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048·Phase 3·CRVS
Recruiting

Primary endpoint: Progression-free survival

InterventionalRandomizedopen150 targetStarted 2024-10Completion 2028-1234 sites · Australia, Canada, United StatesCorvus Pharmaceuticals, Inc.

A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Number of Participants Who Had Dose Limiting Toxicities

Interventionalopen13 targetStarted 2019-02Completion 2027-023 sites · United StatesCity of Hope Medical Center